Immunotherapy of human acute leukaemia.
Conclusions are difficult to draw. In the six studies of immunotherapy of AML discussed, all the three employing BCG and cells showed a prolongation of survival and the major contributing factor to this prolongation of survival was extension of life after relapse. In the three studies using BCG alone only one shows a beneficial effect, but some more time must be allowed to elapse before this can be concluded with confidence.
D000208:Acute Disease; D000818:Animals; D001500:BCG Vaccine / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic; D002648:Child; D002675:Child, Preschool; D006087:Graft vs Host Reaction; D006801:Humans; D007110:Immunity, Active; D007112:Immunity, Maternally-Acquired; D007167:Immunotherapy; D007249:Inflammation / Q000276:immunology; D007938:Leukemia / Q000532:radiotherapy / Q000628:therapy*; D007945:Leukemia, Lymphoid / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D051381:Rats; D012075:Remission, Spontaneous
D001500:BCG Vaccine